Join
Live feed
·
PRReleasevia Quantisnow
Sangamo Therapeutics Inc. logo

Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

ByQuantisnow·Wall Street's wire, on your screen.
SGMO· Sangamo Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SGMO (Sangamo Therapeutics Inc.) and more on Quantisnow.